Which has better earnings and valuation, MANE or CVAC?

CureVac has higher revenue and earnings than Veradermics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradermics N/A N/A N/A N/A N/A CureVac $70.74M 14.78 $175.50M $0.72 6.47

Is MANE or CVAC more profitable?

CureVac has a net margin of 199.92% compared to Veradermics' net margin of 0.00%. Veradermics' return on equity of 0.00% beat CureVac's return on equity. Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A CureVac 199.92% -23.03% -19.09%

Which has stronger valuation and earnings, CVAC or ERAS?

CureVac has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CureVac $70.74M 14.78 $175.50M $0.72 6.47 Erasca N/A N/A -$124.55M -$0.93 N/A

Is CVAC or ERAS more profitable?

CureVac has a net margin of 199.92% compared to Erasca's net margin of 0.00%. CureVac's return on equity of -23.03% beat Erasca's return on equity. Company Net Margins Return on Equity Return on Assets CureVac 199.92% -23.03% -19.09% Erasca N/A -35.31% -29.49%

CureVac (CVAC) Competitors

$4.66 0.00 (0.00%)

As of 06/12/2026

Compare

CVAC vs. MANE, ERAS, CPRX, KNSA, and ORKA

Should you buy CureVac stock or one of its competitors? MarketBeat compares CureVac with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CureVac include Veradermics (MANE), Erasca (ERAS), Catalyst Pharmaceuticals (CPRX), Kiniksa Pharmaceuticals International (KNSA), and Oruka Therapeutics (ORKA). These companies are all part of the "pharmaceutical products" industry.

How does CureVac compare to Veradermics?

Veradermics (NYSE:MANE) and CureVac (NASDAQ:CVAC) are both pharmaceutical products companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

CureVac has a net margin of 199.92% compared to Veradermics' net margin of 0.00%. Veradermics' return on equity of 0.00% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
CureVac	199.92%	-23.03%	-19.09%

In the previous week, Veradermics had 2 more articles in the media than CureVac. MarketBeat recorded 2 mentions for Veradermics and 0 mentions for CureVac. Veradermics' average media sentiment score of 0.54 beat CureVac's score of 0.00 indicating that Veradermics is being referred to more favorably in the media.

Company	Overall Sentiment
Veradermics	Positive
CureVac	Neutral

17.3% of CureVac shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

CureVac has higher revenue and earnings than Veradermics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	N/A	N/A	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Veradermics currently has a consensus target price of $109.00, suggesting a potential upside of 13.65%. CureVac has a consensus target price of $5.50, suggesting a potential upside of 18.03%. Given CureVac's higher probable upside, analysts clearly believe CureVac is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
CureVac	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Veradermics beats CureVac on 6 of the 11 factors compared between the two stocks.

How does CureVac compare to Erasca?

CureVac (NASDAQ:CVAC) and Erasca (NASDAQ:ERAS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, dividends, risk, profitability, analyst recommendations, media sentiment, earnings and institutional ownership.

17.3% of CureVac shares are owned by institutional investors. Comparatively, 67.8% of Erasca shares are owned by institutional investors. 2.2% of CureVac shares are owned by insiders. Comparatively, 14.2% of Erasca shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

CureVac has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market. Comparatively, Erasca has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market.

CureVac presently has a consensus target price of $5.50, suggesting a potential upside of 18.03%. Erasca has a consensus target price of $20.11, suggesting a potential upside of 43.14%. Given Erasca's stronger consensus rating and higher possible upside, analysts clearly believe Erasca is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Erasca	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

CureVac has a net margin of 199.92% compared to Erasca's net margin of 0.00%. CureVac's return on equity of -23.03% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Erasca	N/A	-35.31%	-29.49%

In the previous week, Erasca had 24 more articles in the media than CureVac. MarketBeat recorded 24 mentions for Erasca and 0 mentions for CureVac. CureVac's average media sentiment score of 0.00 beat Erasca's score of -0.20 indicating that CureVac is being referred to more favorably in the media.

Company	Overall Sentiment
CureVac	Neutral
Erasca	Neutral

CureVac has higher revenue and earnings than Erasca. Erasca is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A

Summary

CureVac beats Erasca on 9 of the 15 factors compared between the two stocks.

How does CureVac compare to Catalyst Pharmaceuticals?

CureVac (NASDAQ:CVAC) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

CureVac has a net margin of 199.92% compared to Catalyst Pharmaceuticals' net margin of 37.08%. Catalyst Pharmaceuticals' return on equity of 35.76% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CureVac	199.92%	-23.03%	-19.09%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

In the previous week, Catalyst Pharmaceuticals had 1 more articles in the media than CureVac. MarketBeat recorded 1 mentions for Catalyst Pharmaceuticals and 0 mentions for CureVac. Catalyst Pharmaceuticals' average media sentiment score of 1.43 beat CureVac's score of 0.00 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
CureVac	Neutral
Catalyst Pharmaceuticals	Positive

CureVac has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, indicating that its stock price is 26% less volatile than the broader market.

CureVac presently has a consensus target price of $5.50, suggesting a potential upside of 18.03%. Catalyst Pharmaceuticals has a consensus target price of $32.00, suggesting a potential upside of 2.04%. Given CureVac's higher possible upside, analysts clearly believe CureVac is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CureVac	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

17.3% of CureVac shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 2.2% of CureVac shares are held by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Catalyst Pharmaceuticals has higher revenue and earnings than CureVac. CureVac is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47
Catalyst Pharmaceuticals	$588.99M	6.52	$214.33M	$1.74	18.02

Summary

Catalyst Pharmaceuticals beats CureVac on 13 of the 17 factors compared between the two stocks.

How does CureVac compare to Kiniksa Pharmaceuticals International?

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

CureVac has a net margin of 199.92% compared to Kiniksa Pharmaceuticals International's net margin of 9.69%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat CureVac's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%
CureVac	199.92%	-23.03%	-19.09%

In the previous week, Kiniksa Pharmaceuticals International had 3 more articles in the media than CureVac. MarketBeat recorded 3 mentions for Kiniksa Pharmaceuticals International and 0 mentions for CureVac. Kiniksa Pharmaceuticals International's average media sentiment score of 1.18 beat CureVac's score of 0.00 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the media.

Company	Overall Sentiment
Kiniksa Pharmaceuticals International	Positive
CureVac	Neutral

Kiniksa Pharmaceuticals International has a beta of 0.12, indicating that its stock price is 88% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Comparatively, 2.2% of CureVac shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

CureVac has lower revenue, but higher earnings than Kiniksa Pharmaceuticals International. CureVac is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kiniksa Pharmaceuticals International	$677.56M	5.89	$59.01M	$0.90	57.66
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

Kiniksa Pharmaceuticals International presently has a consensus target price of $60.86, suggesting a potential upside of 17.28%. CureVac has a consensus target price of $5.50, suggesting a potential upside of 18.03%. Given CureVac's higher probable upside, analysts plainly believe CureVac is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89
CureVac	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Kiniksa Pharmaceuticals International beats CureVac on 11 of the 16 factors compared between the two stocks.

How does CureVac compare to Oruka Therapeutics?

Oruka Therapeutics (NASDAQ:ORKA) and CureVac (NASDAQ:CVAC) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

CureVac has higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a lower price-to-earnings ratio than CureVac, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oruka Therapeutics	N/A	N/A	-$105.43M	-$1.94	N/A
CureVac	$70.74M	14.78	$175.50M	$0.72	6.47

In the previous week, Oruka Therapeutics had 6 more articles in the media than CureVac. MarketBeat recorded 6 mentions for Oruka Therapeutics and 0 mentions for CureVac. Oruka Therapeutics' average media sentiment score of 0.19 beat CureVac's score of 0.00 indicating that Oruka Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Oruka Therapeutics	Neutral
CureVac	Neutral

Oruka Therapeutics currently has a consensus target price of $131.30, suggesting a potential upside of 87.87%. CureVac has a consensus target price of $5.50, suggesting a potential upside of 18.03%. Given Oruka Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Oruka Therapeutics is more favorable than CureVac.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82
CureVac	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 17.3% of CureVac shares are owned by institutional investors. 23.5% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 2.2% of CureVac shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

CureVac has a net margin of 199.92% compared to Oruka Therapeutics' net margin of 0.00%. CureVac's return on equity of -23.03% beat Oruka Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-26.16%	-25.00%
CureVac	199.92%	-23.03%	-19.09%

Oruka Therapeutics has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market. Comparatively, CureVac has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

Summary

CureVac beats Oruka Therapeutics on 8 of the 15 factors compared between the two stocks.

Get CureVac News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CVAC vs. The Competition

Export

Metric	CureVac	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.05B	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	6.47	20.00	24.00	24.42
Price / Sales	14.78	306.82	514.36	111.24
Price / Cash	4.73	53.61	27.48	37.92
Price / Book	1.39	8.32	10.54	6.82
Net Income	$175.50M	$23.94M	$3.57B	$337.56M
7 Day Performance	N/A	1.84%	0.60%	1.17%
1 Month Performance	N/A	-0.04%	1.56%	3.16%
1 Year Performance	-16.34%	44.82%	25.42%	30.58%

CureVac Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CVAC CureVac	N/A	$4.66 flat	$5.50 +18.0%	N/A	$1.05B	$70.74M	6.47	880
MANE Veradermics	N/A	$94.16 +4.2%	$109.00 +15.8%	N/A	$3.93B	N/A	N/A	19	Analyst Upgrade Gap Up
ERAS Erasca	2.1632 of 5 stars	$12.44 -3.4%	$20.11 +61.7%	+849.3%	$3.89B	N/A	N/A	120	Trending News
CPRX Catalyst Pharmaceuticals	3.6737 of 5 stars	$31.33 +0.1%	$32.00 +2.2%	+33.3%	$3.83B	$588.99M	18.00	80
KNSA Kiniksa Pharmaceuticals International	4.1369 of 5 stars	$49.89 +1.7%	$60.86 +22.0%	+83.4%	$3.83B	$677.56M	55.32	220	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CVAC) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CureVac (CVAC) Competitors

CVAC vs. MANE, ERAS, CPRX, KNSA, and ORKA

How does CureVac compare to Veradermics?

Summary

How does CureVac compare to Erasca?

Summary

How does CureVac compare to Catalyst Pharmaceuticals?

Summary

How does CureVac compare to Kiniksa Pharmaceuticals International?

Summary

How does CureVac compare to Oruka Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC vs. The Competition

CureVac Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CureVac (CVAC) Competitors

CVAC vs. MANE, ERAS, CPRX, KNSA, and ORKA

How does CureVac compare to Veradermics?

Is MANE or CVAC more profitable?

Does the media prefer MANE or CVAC?

Do institutionals and insiders have more ownership in MANE or CVAC?

Which has better earnings and valuation, MANE or CVAC?

Do analysts prefer MANE or CVAC?

Summary

How does CureVac compare to Erasca?

Do insiders and institutionals hold more shares of CVAC or ERAS?

Which has more risk & volatility, CVAC or ERAS?

Do analysts prefer CVAC or ERAS?

Is CVAC or ERAS more profitable?

Does the media favor CVAC or ERAS?

Which has stronger valuation and earnings, CVAC or ERAS?

Summary

How does CureVac compare to Catalyst Pharmaceuticals?

Is CVAC or CPRX more profitable?

Does the media prefer CVAC or CPRX?

Which has more volatility and risk, CVAC or CPRX?

Do analysts recommend CVAC or CPRX?

Do insiders & institutionals hold more shares of CVAC or CPRX?

Which has stronger earnings and valuation, CVAC or CPRX?

Summary

How does CureVac compare to Kiniksa Pharmaceuticals International?

Is KNSA or CVAC more profitable?

Does the media favor KNSA or CVAC?

Which has more volatility and risk, KNSA or CVAC?

Do institutionals and insiders hold more shares of KNSA or CVAC?

Which has higher earnings and valuation, KNSA or CVAC?

Do analysts prefer KNSA or CVAC?

Summary

How does CureVac compare to Oruka Therapeutics?

Which has better valuation and earnings, ORKA or CVAC?

Does the media favor ORKA or CVAC?

Do analysts recommend ORKA or CVAC?

Do insiders and institutionals hold more shares of ORKA or CVAC?

Is ORKA or CVAC more profitable?

Which has more volatility & risk, ORKA or CVAC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVAC vs. The Competition

CureVac Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools